MedTrace Logo

Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

NCT00421018 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2012-08-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma

Conditions

  • Allergic Asthma

Interventions

DRUG

Single corticosteroid inhalers and Singulair

Treatment steps according to preset algorithm

Sponsors & Collaborators

  • Region Stockholm

    collaborator OTHER_GOV

  • Aerocrine AB

    collaborator INDUSTRY

  • Phadia AB

    collaborator UNKNOWN

  • Meda AB

    collaborator UNKNOWN

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Swedish Council for Working Life and Social Research

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Uppsala University

    collaborator OTHER

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Kjell Alving, PhD · Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00421018 on ClinicalTrials.gov